A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Apr 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Venetoclax (Primary)
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Sponsors AbbVie; AbbVie Germany

15 Apr 2024 Planned End Date changed from 19 Dec 2027 to 22 Jun 2027.
15 Apr 2024 Planned primary completion date changed from 18 Dec 2027 to 22 Jun 2027.
15 Apr 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com